ReviewPathogens (Basel, Switzerland)2020
Drug Discovery against
Review in Pathogens (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 65 citations in OpenAlex.
- Fatal brain infection in early life: primary amoebic meningoencephalitis caused by Naegleria fowleri in neonates and infants.BMC infectious diseases · 2026Pooled it
- Pooled it
- Article
- Vaccines for microbial eye diseases in the era of data science: opportunities and challenges.Frontiers in immunology · 2026Review
- A Review on Phytochemistry, Ethnopharmacology, and Antiparasitic Potential ofPharmaceuticals (Basel, Switzerland) · 2025Review
- Exploring novel thiazole-based minor groove binding agents as potential therapeutic agents against pathogenicRSC medicinal chemistry · 2025Article
- Article
- The pathogenesis, risk factors, diagnosis and treatment of Acanthamoeba keratitis.Frontiers in medicine · 2025Review
- Drug modifications: graphene oxide-chitosan loading enhanced anti-amoebic effects of pentamidine and doxycycline.Parasitology research · 2024Article
- Anti-Acanthamoeba metallopharmaceuticals: Amoebicidal activity and synergistic effect of copper(II) coordination compound.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2024Article
- Strathclyde minor groove binders (S-MGBs) with activity against Acanthamoeba castellanii.The Journal of antimicrobial chemotherapy · 2024Article
- Metal Oxide Nanoparticles Exhibit Anti-Acanthamoeba castellanii Properties by Inducing Necrotic Cell Death.Acta parasitologica · 2024Article
- Inhibitory and anti-adherent effects ofVeterinary world · 2024Article
- Caffeic Acid Phosphanium Derivatives: Potential Selective Antitumor, Antimicrobial and Antiprotozoal Agents.International journal of molecular sciences · 2024Article
- Novel anti-Frontiers in cellular and infection microbiology · 2024Article
- Cell death of Acanthamoeba castellanii following exposure to antimicrobial agents commonly included in contact lens disinfecting solutions.Parasitology research · 2023Article
- Effect of embelin on inhibition of cell growth and induction of apoptosis in Acanthamoeba castellanii.Archives of microbiology · 2023Article
- Applications of Polyaniline-Based Molybdenum Disulfide Nanoparticles against Brain-Eating Amoebae.ACS omega · 2023Article
- Amoebicidal activity of cationic carbosilane dendrons derived with 4-phenylbutyric acid against Acanthamoeba griffini and Acanthamoeba polyphaga trophozoites and cysts.Scientific reports · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
Although major strides have been made in developing and testing various anti-acanthamoebic drugs, recurrent infections, inadequate treatment outcomes, health complications, and side effects associated with the use of currently available drugs necessitate the development of more effective and safe therapeutic regimens. For any new anti-acanthamoebic drugs to be more effective, they must have either superior potency and safety or at least comparable potency and an improved safety profile compared to the existing drugs. The development of the so-called 'next-generation' anti-acanthamoebic agents to address this challenge is an active area of research. Here, we review the current status of anti-acanthamoebic drugs and discuss recent progress in identifying novel pharmacological targets and new approaches, such as drug repurposing, development of small interfering RNA (siRNA)-based therapies and testing natural products and their derivatives. Some of the discussed approaches have the potential to change the therapeutic landscape of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.